Immunotherapy company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) on Monday announced updated results from the Phase 1/2 trial of SAR443579/IPH6101 (SAR'579), a first-in-class NK cell engager targeting CD123.

Developed under a joint research collaboration with Sanofi (Nasdaq: SNY), the investigational drug is being tested for relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS).

Presented at the European Hematology Association 2024 Congress on 16 June 2024, the data revealed that SAR'579 achieved five complete remissions (four CR, one CRi) at a 1 mg/kg dose, with three patients showing durable complete remission for over 10 months. SAR'579 demonstrated a favorable safety profile, tolerated at doses up to 6 mg/kg.

The study treated 59 patients, mostly with R/R AML, across 11 dose levels. A median treatment duration of 7.9 weeks was reported, and two patients remained on maintenance therapy as of the data cutoff. These findings will inform the recommended doses for the Phase 2 trial.

SAR'579 is part of Innate's ANKET platform, which focuses on developing multi-specific NK cell engagers to treat cancer. Innate and Sanofi's collaboration includes a research agreement from 2016, under which Innate could receive up to EUR400m in milestone payments and royalties on net sales.

Under a license agreement entered in December 2022, Sanofi licensed IPH62 and IPH67 and has the option for one additional target. According to the terms of the 2022 agreement, Innate Pharma is eligible to up to EUR1.35bn in development and commercial milestone payments as well as royalties on net sales.

Innate Pharma, headquartered in Marseille, France, with a US office in Rockville, MD, specialises in developing immunotherapies for cancer, with partnerships including Sanofi and AstraZeneca.